• Representation of a Florida-based developer of pharmaceuticals in all aspects of SEC compliance. Our attorneys also handled its initial private placement, initial public offering and subsequent public and private securities offerings. Ongoing representation includes nearly $1 billion in various transactions, including acquisitions and reorganization.
  • Representation of a closed-door pharmacy in a $3 million sale to a strategic buyer.
  • Representation of Vital Pharmaceuticals: After notice and hearing, the trial court granted a temporary injunction against former employees of Vital Pharmaceuticals, but did not require a bond. The injunction was soon dissolved, and that order was affirmed on appeal without a written decision. Thereafter, the wrongfully enjoined employee/defendants sought and were awarded their attorneys’ fees as damages. On appeal by Vital Pharmaceuticals, the Fourth DCA reversed after oral argument. The court held that the injunction bond required by rule 1.610(b), Fla. R. Civ. P., is the sole source of any damages for a wrongful injunction. This decision demonstrates the importance—to both sides—of an injunction bond. (Vital Pharmaceuticals, Inc. v. Professional Supplements, LLC, No. 4D15-1123)
  • Representation of a retail pharmacy in a $1 million sale to a public company.

Discover Your
Career with Broad and Cassel

Search all openings by completing the following form.

Advanced Search

By submitting your search, you acknowledge that you are leaving Broad and Cassel's website and are being redirected to a third-party website. Broad and Cassel is not responsible for the content or security of third-party sites. Any information that you submit to Broad and Cassel via the third-party website may not be encrypted. Also, please be aware that the security and privacy policies on third-party sites may be different than Broad and Cassel policies.